L-arginine administration reverses anemia associated with renal disease

International Journal of Hematology

Volumn 86, Issue 2, 2007, Pages 126-129

  Tarumoto, Takahisa ^a   Imagawa, Shigehiko ^b   Kobayashi, Makoto ^c   Hirayama, Aki ^b   Ozawa, Keiya ^a   Nagasawa, Toshiro ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c Arikawa Hospital   (Japan)

Author keywords

Anemia associated with renal disease; Erythropoietin; Hemoglobin; L Arginine; Renal failure

Indexed keywords

ARGININE; ERYTHROPOIETIN; HEMOGLOBIN;

AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIALYSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANEMIA; ARGININE; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; REMISSION INDUCTION; RETICULOCYTE COUNT;

EID: 34548777531     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06212     Document Type: Article

References (17)

1. Semenza GL. Perspective on oxygen sensing. Cell. 1999;98:281-284.
2. Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood. 1997;89:1430-1439.
3. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985;28:1-5.
4. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev. 1996;76:839-885.
5. Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int Suppl. 2001;78:S67-S72.
6. G-monomethyl L-arginine in human end-stage renal failure patients on regular haemodialysis. Exp Physiol. 1996;81:475-481.
7. G-monomethyl L-arginine inhibits erythropoietin gene expression by stimulating GATA-2. Blood. 2000;96:1716-1722.
8. Imagawa S, Tarumoto T, Suzuki N, et al. L-Arginine rescues decreased erythropoietin gene expression by stimulating GATA-2 with L-NMMA. Kidney Int. 2002;61:396-404.
9. Jelkmann W. Renal erythropoietin: properties and production. Rev Physiol Biochem Pharmacol. 1986;104:139-215.
10. Mizoguchi H, Ohta K, Suzuki T, et al. Basic conditions for radioimmunoassay of erythropoietin, and plasma levels of erythropoietin in normal subjects and anemic patients. Nippon Ketsueki Gakkai Zasshi. 1987;50:15-24.
11. Lacombe C, Da Silva JL, Bruneval P, et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest. 1988;81:620-623.
12. McGonigle RJS, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and erythropoiesis in renal insufficiency. Kidney Int. 1984;25:437-444.
13. Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W. Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease. Kidney Int. 1987;31:1205-1209.
14. Gray GA, Schott C, Julou-Schaeffer G, Fleming I, Parratt JR, Stoclet JC. The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. Br J Pharmacol. 1991;103:1218-1224.
15. Hecker M, Sessa WC, Harris HJ, Änggård EE, Vane JR. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci U S A. 1990;87:8612-8616.
16. G-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. Biochem Biophys Res Commun. 1990;167:1037-1043.
17. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992;80:1639-1647.